Copyright Reports & Markets. All rights reserved.

Global and United States Gynecological Cancer Diagnostics Market Report & Forecast 2022-2028

Request for Sample of this report
Buy now

Table of Contents

    1 Study Coverage

    • 1.1 Gynecological Cancer Diagnostics Revenue in Gynecological Cancer Diagnostics Business (2017-2022) & (US$ Million) Introduction
    • 1.2 Global Gynecological Cancer Diagnostics Outlook 2017 VS 2022 VS 2028
      • 1.2.1 Global Gynecological Cancer Diagnostics Market Size for the Year 2017-2028
      • 1.2.2 Global Gynecological Cancer Diagnostics Market Size for the Year 2017-2028
    • 1.3 Gynecological Cancer Diagnostics Market Size, United States VS Global, 2017 VS 2022 VS 2028
      • 1.3.1 The Market Share of United States Gynecological Cancer Diagnostics in Global, 2017 VS 2022 VS 2028
      • 1.3.2 The Growth Rate of Gynecological Cancer Diagnostics Market Size, United States VS Global, 2017 VS 2022 VS 2028
    • 1.4 Gynecological Cancer Diagnostics Market Dynamics
      • 1.4.1 Gynecological Cancer Diagnostics Industry Trends
      • 1.4.2 Gynecological Cancer Diagnostics Market Drivers
      • 1.4.3 Gynecological Cancer Diagnostics Market Challenges
      • 1.4.4 Gynecological Cancer Diagnostics Market Restraints
    • 1.5 Study Objectives
    • 1.6 Years Considered

    2 Gynecological Cancer Diagnostics by Type

    • 2.1 Gynecological Cancer Diagnostics Market Segment by Type
      • 2.1.1 Genetic Counseling Test
      • 2.1.2 Cancer Risk Test
      • 2.1.3 Kits Test
    • 2.2 Global Gynecological Cancer Diagnostics Market Size by Type (2017, 2022 & 2028)
    • 2.3 Global Gynecological Cancer Diagnostics Market Size by Type (2017-2028)
    • 2.4 United States Gynecological Cancer Diagnostics Market Size by Type (2017, 2022 & 2028)
    • 2.5 United States Gynecological Cancer Diagnostics Market Size by Type (2017-2028)

    3 Gynecological Cancer Diagnostics by Application

    • 3.1 Gynecological Cancer Diagnostics Market Segment by Application
      • 3.1.1 Gestational Trophoblastic Disease Diagnostics
      • 3.1.2 Endometrial Cancer Diagnostics
      • 3.1.3 Peritoneal Cancer Diagnostics
      • 3.1.4 Cervical Cancer Diagnostics
      • 3.1.5 Ovarian Cancer Diagnostics
      • 3.1.6 Vaginal Cancer Diagnostics
      • 3.1.7 Uterine Cancer Diagnostics
      • 3.1.8 Vulvar Cancer Diagnostics
    • 3.2 Global Gynecological Cancer Diagnostics Market Size by Application (2017, 2022 & 2028)
    • 3.3 Global Gynecological Cancer Diagnostics Market Size by Application (2017-2028)
    • 3.4 United States Gynecological Cancer Diagnostics Market Size by Application (2017, 2022 & 2028)
    • 3.5 United States Gynecological Cancer Diagnostics Market Size by Application (2017-2028)

    4 Global Gynecological Cancer Diagnostics Competitor Landscape by Company

    • 4.1 Global Gynecological Cancer Diagnostics Market Size by Company
      • 4.1.1 Top Global Gynecological Cancer Diagnostics Companies Ranked by Revenue (2021)
      • 4.1.2 Global Gynecological Cancer Diagnostics Revenue by Player (2017-2022)
    • 4.2 Global Gynecological Cancer Diagnostics Concentration Ratio (CR)
      • 4.2.1 Gynecological Cancer Diagnostics Market Concentration Ratio (CR) (2017-2022)
      • 4.2.2 Global Top 5 and Top 10 Largest Companies of Gynecological Cancer Diagnostics in 2021
      • 4.2.3 Global Gynecological Cancer Diagnostics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
    • 4.3 Global Gynecological Cancer Diagnostics Headquarters, Revenue in Gynecological Cancer Diagnostics Business (2017-2022) & (US$ Million) Type
      • 4.3.1 Global Gynecological Cancer Diagnostics Headquarters and Area Served
      • 4.3.2 Global Gynecological Cancer Diagnostics Companies Revenue in Gynecological Cancer Diagnostics Business (2017-2022) & (US$ Million) Type
      • 4.3.3 Date of International Companies Enter into Gynecological Cancer Diagnostics Market
    • 4.4 Companies Mergers & Acquisitions, Expansion Plans
    • 4.5 United States Gynecological Cancer Diagnostics Market Size by Company
      • 4.5.1 Top Gynecological Cancer Diagnostics Players in United States, Ranked by Revenue (2021)
      • 4.5.2 United States Gynecological Cancer Diagnostics Revenue by Players (2020, 2021 & 2022)

    5 Global Gynecological Cancer Diagnostics Market Size by Region

    • 5.1 Global Gynecological Cancer Diagnostics Market Size by Region: 2017 VS 2022 VS 2028
    • 5.2 Global Gynecological Cancer Diagnostics Market Size by Region (2017-2028)
      • 5.2.1 Global Gynecological Cancer Diagnostics Market Size by Region: 2017-2022
      • 5.2.2 Global Gynecological Cancer Diagnostics Market Size by Region (2023-2028)

    6 Segment in Region Level & Country Level

    • 6.1 North America
      • 6.1.1 North America Gynecological Cancer Diagnostics Market Size YoY Growth 2017-2028
      • 6.1.2 North America Gynecological Cancer Diagnostics Market Facts & Figures by Country (2017, 2022 & 2028)
      • 6.1.3 United States
      • 6.1.4 Canada
    • 6.2 Asia-Pacific
      • 6.2.1 Asia-Pacific Gynecological Cancer Diagnostics Market Size YoY Growth 2017-2028
      • 6.2.2 Asia-Pacific Gynecological Cancer Diagnostics Market Facts & Figures by Region (2017, 2022 & 2028)
      • 6.2.3 China
      • 6.2.4 Japan
      • 6.2.5 South Korea
      • 6.2.6 India
      • 6.2.7 Australia
      • 6.2.8 China Taiwan
      • 6.2.9 Indonesia
      • 6.2.10 Thailand
      • 6.2.11 Malaysia
    • 6.3 Europe
      • 6.3.1 Europe Gynecological Cancer Diagnostics Market Size YoY Growth 2017-2028
      • 6.3.2 Europe Gynecological Cancer Diagnostics Market Facts & Figures by Country (2017, 2022 & 2028)
      • 6.3.3 Germany
      • 6.3.4 France
      • 6.3.5 U.K.
      • 6.3.6 Italy
      • 6.3.7 Russia
    • 6.4 Latin America
      • 6.4.1 Latin America Gynecological Cancer Diagnostics Market Size YoY Growth 2017-2028
      • 6.4.2 Latin America Gynecological Cancer Diagnostics Market Facts & Figures by Country (2017, 2022 & 2028)
      • 6.4.3 Mexico
      • 6.4.4 Brazil
      • 6.4.5 Argentina
    • 6.5 Middle East and Africa
      • 6.5.1 Middle East and Africa Gynecological Cancer Diagnostics Market Size YoY Growth 2017-2028
      • 6.5.2 Middle East and Africa Gynecological Cancer Diagnostics Market Facts & Figures by Country (2017, 2022 & 2028)
      • 6.5.3 Turkey
      • 6.5.4 Saudi Arabia
      • 6.5.5 UAE

    7 Company Profiles

    • 7.1 UT Southwestern
      • 7.1.1 UT Southwestern Company Details
      • 7.1.2 UT Southwestern Business Overview
      • 7.1.3 UT Southwestern Gynecological Cancer Diagnostics Introduction
      • 7.1.4 UT Southwestern Revenue in Gynecological Cancer Diagnostics Business (2017-2022)
      • 7.1.5 UT Southwestern Recent Development
    • 7.2 Abramson Cancer Center
      • 7.2.1 Abramson Cancer Center Company Details
      • 7.2.2 Abramson Cancer Center Business Overview
      • 7.2.3 Abramson Cancer Center Gynecological Cancer Diagnostics Introduction
      • 7.2.4 Abramson Cancer Center Revenue in Gynecological Cancer Diagnostics Business (2017-2022)
      • 7.2.5 Abramson Cancer Center Recent Development
    • 7.3 Northwestern Medicine
      • 7.3.1 Northwestern Medicine Company Details
      • 7.3.2 Northwestern Medicine Business Overview
      • 7.3.3 Northwestern Medicine Gynecological Cancer Diagnostics Introduction
      • 7.3.4 Northwestern Medicine Revenue in Gynecological Cancer Diagnostics Business (2017-2022)
      • 7.3.5 Northwestern Medicine Recent Development
    • 7.4 Sysmex Europe SE
      • 7.4.1 Sysmex Europe SE Company Details
      • 7.4.2 Sysmex Europe SE Business Overview
      • 7.4.3 Sysmex Europe SE Gynecological Cancer Diagnostics Introduction
      • 7.4.4 Sysmex Europe SE Revenue in Gynecological Cancer Diagnostics Business (2017-2022)
      • 7.4.5 Sysmex Europe SE Recent Development
    • 7.5 Fujirebio
      • 7.5.1 Fujirebio Company Details
      • 7.5.2 Fujirebio Business Overview
      • 7.5.3 Fujirebio Gynecological Cancer Diagnostics Introduction
      • 7.5.4 Fujirebio Revenue in Gynecological Cancer Diagnostics Business (2017-2022)
      • 7.5.5 Fujirebio Recent Development
    • 7.6 Premier Health
      • 7.6.1 Premier Health Company Details
      • 7.6.2 Premier Health Business Overview
      • 7.6.3 Premier Health Gynecological Cancer Diagnostics Introduction
      • 7.6.4 Premier Health Revenue in Gynecological Cancer Diagnostics Business (2017-2022)
      • 7.6.5 Premier Health Recent Development
    • 7.7 Agilent Technologies, Inc
      • 7.7.1 Agilent Technologies, Inc Company Details
      • 7.7.2 Agilent Technologies, Inc Business Overview
      • 7.7.3 Agilent Technologies, Inc Gynecological Cancer Diagnostics Introduction
      • 7.7.4 Agilent Technologies, Inc Revenue in Gynecological Cancer Diagnostics Business (2017-2022)
      • 7.7.5 Agilent Technologies, Inc Recent Development
    • 7.8 ARUP Laboratories
      • 7.8.1 ARUP Laboratories Company Details
      • 7.8.2 ARUP Laboratories Business Overview
      • 7.8.3 ARUP Laboratories Gynecological Cancer Diagnostics Introduction
      • 7.8.4 ARUP Laboratories Revenue in Gynecological Cancer Diagnostics Business (2017-2022)
      • 7.8.5 ARUP Laboratories Recent Development
    • 7.9 CENTOGENE
      • 7.9.1 CENTOGENE Company Details
      • 7.9.2 CENTOGENE Business Overview
      • 7.9.3 CENTOGENE Gynecological Cancer Diagnostics Introduction
      • 7.9.4 CENTOGENE Revenue in Gynecological Cancer Diagnostics Business (2017-2022)
      • 7.9.5 CENTOGENE Recent Development
    • 7.10 F. Hoffmann-La Roche Ltd
      • 7.10.1 F. Hoffmann-La Roche Ltd Company Details
      • 7.10.2 F. Hoffmann-La Roche Ltd Business Overview
      • 7.10.3 F. Hoffmann-La Roche Ltd Gynecological Cancer Diagnostics Introduction
      • 7.10.4 F. Hoffmann-La Roche Ltd Revenue in Gynecological Cancer Diagnostics Business (2017-2022)
      • 7.10.5 F. Hoffmann-La Roche Ltd Recent Development
    • 7.11 Fulgent Genetics, Inc
      • 7.11.1 Fulgent Genetics, Inc Company Details
      • 7.11.2 Fulgent Genetics, Inc Business Overview
      • 7.11.3 Fulgent Genetics, Inc Gynecological Cancer Diagnostics Introduction
      • 7.11.4 Fulgent Genetics, Inc Revenue in Gynecological Cancer Diagnostics Business (2017-2022)
      • 7.11.5 Fulgent Genetics, Inc Recent Development
    • 7.12 Invitae Corporation
      • 7.12.1 Invitae Corporation Company Details
      • 7.12.2 Invitae Corporation Business Overview
      • 7.12.3 Invitae Corporation Gynecological Cancer Diagnostics Introduction
      • 7.12.4 Invitae Corporation Revenue in Gynecological Cancer Diagnostics Business (2017-2022)
      • 7.12.5 Invitae Corporation Recent Development
    • 7.13 Myriad Genetics, Inc
      • 7.13.1 Myriad Genetics, Inc Company Details
      • 7.13.2 Myriad Genetics, Inc Business Overview
      • 7.13.3 Myriad Genetics, Inc Gynecological Cancer Diagnostics Introduction
      • 7.13.4 Myriad Genetics, Inc Revenue in Gynecological Cancer Diagnostics Business (2017-2022)
      • 7.13.5 Myriad Genetics, Inc Recent Development
    • 7.14 BGI Group
      • 7.14.1 BGI Group Company Details
      • 7.14.2 BGI Group Business Overview
      • 7.14.3 BGI Group Gynecological Cancer Diagnostics Introduction
      • 7.14.4 BGI Group Revenue in Gynecological Cancer Diagnostics Business (2017-2022)
      • 7.14.5 BGI Group Recent Development

    8 Research Findings and Conclusion

      9 Appendix

      • 9.1 Research Methodology
        • 9.1.1 Methodology/Research Approach
        • 9.1.2 Data Source
      • 9.2 Author Details

      Summary:

      Market Analysis and Insights: Global and United States Gynecological Cancer Diagnostics Market
      This report focuses on global and United States Gynecological Cancer Diagnostics market, also covers the segmentation data of other regions in regional level and county level.
      Due to the COVID-19 pandemic, the global Gynecological Cancer Diagnostics market size is estimated to be worth US$ million in 2022 and is forecast to a readjusted size of US$ million by 2028 with a CAGR of % during the forecast period 2022-2028. Fully considering the economic change by this health crisis, by Type, Genetic Counseling Test accounting for % of the Gynecological Cancer Diagnostics global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR from 2022 to 2028. While by Application, Gestational Trophoblastic Disease Diagnostics was the leading segment, accounting for over percent market share in 2021, and altered to an % CAGR throughout this forecast period.
      In United States the Gynecological Cancer Diagnostics market size is expected to grow from US$ million in 2021 to US$ million by 2028, at a CAGR of % during the forecast period 2022-2028.
      Global Gynecological Cancer Diagnostics Scope and Market Size
      Gynecological Cancer Diagnostics market is segmented by region (country), players, by Type and by Application. Players, stakeholders, and other participants in the global Gynecological Cancer Diagnostics market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by region (country), by Type and by Application for the period 2017-2028.
      For United States market, this report focuses on the Gynecological Cancer Diagnostics market size by players, by Type and by Application, for the period 2017-2028. The key players include the global and local players, which play important roles in United States.
      Segment by Type, the Gynecological Cancer Diagnostics market is segmented into
      Genetic Counseling Test
      Cancer Risk Test
      Kits Test
      Segment by Application, the Gynecological Cancer Diagnostics market is segmented into
      Gestational Trophoblastic Disease Diagnostics
      Endometrial Cancer Diagnostics
      Peritoneal Cancer Diagnostics
      Cervical Cancer Diagnostics
      Ovarian Cancer Diagnostics
      Vaginal Cancer Diagnostics
      Uterine Cancer Diagnostics
      Vulvar Cancer Diagnostics
      Regional and Country-level Analysis
      North America
      United States
      Canada
      Europe
      Germany
      France
      U.K.
      Italy
      Russia
      Asia-Pacific
      China
      Japan
      South Korea
      India
      Australia
      China Taiwan
      Indonesia
      Thailand
      Malaysia
      Latin America
      Mexico
      Brazil
      Argentina
      Middle East & Africa
      Turkey
      Saudi Arabia
      UAE
      Competitive Landscape and Gynecological Cancer Diagnostics Market Share Analysis
      Gynecological Cancer Diagnostics market competitive landscape provides details and data information by players. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2017-2022. It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by players for the period 2017-2022. Details included are company description, major business, company total revenue and the sales, revenue generated in Gynecological Cancer Diagnostics business, the date to enter into the Gynecological Cancer Diagnostics market, Revenue in Gynecological Cancer Diagnostics Business (2017-2022) & (US$ Million) introduction, recent developments, etc.
      The major vendors covered:
      UT Southwestern
      Abramson Cancer Center
      Northwestern Medicine
      Sysmex Europe SE
      Fujirebio
      Premier Health
      Agilent Technologies, Inc
      ARUP Laboratories
      CENTOGENE
      F. Hoffmann-La Roche Ltd
      Fulgent Genetics, Inc
      Invitae Corporation
      Myriad Genetics, Inc
      BGI Group
      Buy now